A pharmacist-led program to discontinue duplicate incretin therapy with GLP-1 agonists and DPP-4 inhibitors for diabetes can optimize therapy and save more than $7,500 per beneficiary, or an annualized program savings estimate of $3.5 million, a new study has found.